We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

Shares of GSK PLC GSK inched up 0.78% to £13.59 Friday, on what proved to be an all-around great trading session for the ...

Shares of GSK PLC GSK advanced 1.58% to £13.49 Thursday, on what proved to be an all-around favorable trading session for the ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $32.7 which represents a decrease of $-0.39 or -1.18% from the prior close of $33.09. The stock opened at $32.74 and touched a low of ...

Check the time stamp on this data. Updated AI-Generated Signals for Gsk Plc American Depositary Shares (each Representing Two ...

GSK plc (GSK) stock saw a decline, ending the day at $33.09 which represents a decrease of $-0.66 or -1.96% from the prior close of $33.75. The stock opened at $33.26 and touched a low of $33.01 ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.

ST Germain D J Co. Inc. increased its stake in GSK plc (NYSE:GSK – Free Report) by 195.5% during the fourth quarter, ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...